Bionaut Pharmaceuticals and AnalytiCon Discovery Collaborate for Optimization of Novel Class of Anti-Cancer Compounds
Bionaut Pharmaceuticals, Inc. and AnalytiCon Discovery GmbH announced a service and collaboration agreement to identify novel anti-cancer compounds that inhibit the ability of tumor cells to survive stress conditions. Bionaut will provide to the collaboration a series of compounds that have shown potent in vivo activity in various human tumor xenograft models and use its Sentinel® Pathway Reporter System to validate new compounds. AnalytiCon will apply its natural product and medicinal chemistry expertise to optimize the activity and selectivity of these compounds for further pre-clinical development by Bionaut. Financial terms were not disclosed.
"We are delighted to have the chemistry team at AnalytiCon developing novel analogues for our lead program in cancer," said Thomas Klein, Chief Operating Officer of Bionaut. "We believe their unique combination of expertise in natural products and analog medicinal chemistry will provide the fastest route to identify novel drug candidates to take forward towards human clinical studies."
"The novel biological screening capabilities of Bionaut, combined with our exceptional integrated natural productrelated expertise, make this a unique partnership," said Lutz Müller-Kuhrt, Ph.D., CEO of AnalytiCon Discovery. "Bionaut's whole cell assays, which were used to identify this class of compounds that target tumor cells' response to stress, can also be used to rapidly validate the selectivity and efficacy of the compound analogues we develop for Bionaut."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Heavy Metals Weigh on Unborn Babies’ Health - Researchers explain workings of placental transport systems: spotlight on mercury and iron
Amorfix awarded "Life Science Company of the Year" for moving innovative products into commercialization

Anti-inflammatory drug protects against lethal inflammation from COVID-19 in animal models
Artemis Pharmaceuticals and Merck Collaborate to Develop Customized Mouse Models
Prometic obtains controlling stake in Pathogen Removal and Diagnostic Technologies Inc. - Non Cash Transaction results in ProMetic increasing its holding of common stock from 26% to 77%
